Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
BI

BIIBStock

Nasdaq Global Select Market · Healthcare · US

$250.79 last close 2026-11-17
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment BIIB's does — no target price to set, unlike a price alert.

Sharia status
COMPLIANT
Per our in-house ratio engine · assessed 2026-09-30
7 of 7 pass our own screen — all 7 agree here
🕌 Held by HLAL · MNZL HTR non-permissible income 1.26%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
🟡 BULLISH LEAN
The main driver: outperforming the market by 7.2%, RSI in healthy zone, Wall Street broadly bullish. More signals...
Scores: 3 bullish / 2 bearish
52
of 100
Setup confidence — system conviction, not win probabilityC

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MOM · SCALP
Entry
$251.82
Stop
$245.99
Target
$263.49
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure3 of 5 timeframes bullish · 39.1% aligned
VWAPPrice below VWAP ($252.32)
VolumeRelative volume 2.9× the 20-day average
Momentum10-day rate of change +0.7%
Overall readBULLISH LEAN

BIIB is currently considered halal (Sharia-compliant), per our in-house ratio engine (last assessed 2026-09-30). See the full ratio breakdown and business-activity screen below for the reasoning.

This sits among 435 compliant Healthcare stocks we track. See compliant Healthcare stocks →

Market & analysts
Wall Street consensus
BUY
43 analysts
Institutional own.
99.6%
of shares
Momentum (10d)
+0.7%
rate of change
SMC grade
C · 52
39.1% aligned
🕌 HLAL, MNZL
Held by real halal ETF(s)
1.26%
Non-permissible income — HTR, from filings (2025-12-31)
C · 52
SMC grade — 39.1% timeframe alignment
+0.7%
Rate of change (10d)
BUY
Wall Street consensus (43)
99.6%
Institutional ownership

How the status reached this point

Compliant · status tracked since Nov 17, 2026

No change to BIIB’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 17, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $37.5B as of 2026-11-16. At the 2026-11-17 close it is about $37.1B (the stored market cap moved by the share price since, not a new share count), and at that cap AAOIFI's interest-bearing debt ratio would read 19.9% (19.7% at the stored cap, against a 30% line) and interest-bearing investments ratio would read 3.5% (3.5% at the stored cap, against a 30% line). The published verdict changes only when the company is re-screened.

Business activity: cleared (no excluded categories detected)

AAOIFI Pass 3 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing debt 19.72% 30.00% Pass(10.3pp buffer)
Interest-bearing investments 3.47% 30.00% Pass(26.5pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
Usmani Pass 4 of 4 ratios pass
RatioValueThresholdResult
Interest-bearing debt 23.09% 33.00% Pass(9.9pp buffer)
Interest-bearing investments 4.07% 33.00% Pass(28.9pp buffer)
Non-liquid assets 95.93% at least 20.00% Pass(75.9pp above the floor)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
MSCI Pass from an earlier screen 3 of 3 ratios pass

This Pass was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable not measured. The earlier verdict stands until a screen can decide it.

RatioValueThresholdResult
Interest-bearing debt 23.09% 33.33% Pass(10.2pp buffer)
Cash + interest-bearing securities 4.07% 33.33% Pass(29.3pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
FTSE Pass from an earlier screen 3 of 3 ratios pass

This Pass was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable not measured. The earlier verdict stands until a screen can decide it.

RatioValueThresholdResult
Interest-bearing debt 22.75% 33.33% Pass(10.6pp buffer)
Cash + interest-bearing securities 4.07% 33.33% Pass(29.3pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
Dow Jones Islamic Market Pass from an earlier screen 3 of 3 ratios pass

This Pass was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 29.27% 33.00% Pass(3.7pp buffer)
Cash + interest-bearing securities 5.16% 33.00% Pass(27.8pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
S&P Shariah Pass from an earlier screen 3 of 3 ratios pass

This Pass was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 26.81% 33.00% Pass(6.2pp buffer)
Cash + interest-bearing securities 4.72% 49.00% Pass(44.3pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)
MSCI M-Series Pass from an earlier screen 3 of 3 ratios pass

This Pass was decided by an earlier screen. The figures below are from the latest filing, which could not decide it on its own: accounts receivable not measured. The earlier verdict stands until a screen can decide it.

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Interest-bearing debt 26.81% 33.33% Pass(6.5pp buffer)
Cash + interest-bearing securities 4.72% 33.33% Pass(28.6pp buffer)
Non-permissible income 1.26% 5.00% Pass(3.7pp buffer)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

AAOIFI Standard 21 (% of market cap)non permissible income ratio 3.7pts
Usmani (% of total assets)non permissible income ratio 3.7pts
Usmani (% of total assets)debt ratio 9.9pts

The numbers the ratios are built from

Read from BIIB's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $9.9B 2025-12-31 Revenues
Interest-bearing debtShort and long-term borrowings $7.3B 2026-09-30 LongTermDebt
Cash and interest-bearing securitiesCash, equivalents and marketable securities $1.3B 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent
Total assetsBalance sheet total $32.1B 2026-09-30 Assets
Market capDenominator for AAOIFI $37.5B live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $27.2B 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $24.9B 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $125.0M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet as of 2026-09-30. Income statement as of 2025-12-31. Screened 2026-11-16.

Filing links appear after the next screen: this row was screened before filing citations were recorded.

  • Total assets$32.1B
    Assets · balance sheet as of 2026-09-30
  • Interest-bearing debt$7.3B
    LongTermDebt · balance sheet as of 2026-09-30
  • Cash and interest-bearing securities$1.3B
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents, AvailableForSaleSecuritiesDebtSecuritiesCurrent · balance sheet as of 2026-09-30
  • Revenue$9.9B
    Revenues · income statement as of 2025-12-31
  • Interest income (non-permissible)$125.0M
    InvestmentIncomeInterest · income statement as of 2025-12-31
  • Market cap$37.5B
    Market-data quote at screen time, 2026-11-16 · not a filing figure, so no link

What changed, and when

Verdict history for BIIB. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-09-07 No change recorded No verdict change for BIIB has been recorded since tracking began. The scan ledger records that the compliance detectors ran, not which symbols each pass covered.

Tracked since 2026-09-07.

Revenue by business segment

BIIB’s 10-K reports all $9.9B of its revenue for the fiscal year 2025-01-01 to 2025-12-31 under one line, Reportable Segment, and does not break it down further.

These are the company’s own segment names and figures. They do not say whether a line of business is permissible; our business-activity screen does.

Source: 10-K filed 2026-02-06 (accession 0000875045-26-000013), read from its XBRL on SEC EDGAR.

What would change the status

The headline verdict is the majority of the decided ratio standards — 7 pass and 0 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-16.

The ratios that move with the share price

AAOIFI's debt ratio is $7.4B debt (operating leases included, as the screen counts it) over a market cap of $37.5B (as of 2026-11-16), 19.7% against a 30% line.

At the 2026-11-17 close the market cap is about $37.1B (the stored cap moved by the share price since), so this ratio would read 19.9%; the line is -34% from there. The published status changes only when the company is re-screened.

It would fail if the market cap fell to $24.7B (-34%), about $166.90 a share against $253.92 implied by the screen's own figures.

AAOIFI would then fail.

At the screen's market cap, debt would have to rise by $3.9B to reach the line.

AAOIFI would then fail.

AAOIFI's investments ratio (3.5% against a 30% line) would only fail if the market cap fell by 88%, to $4.3B. At the 2026-11-17 close it would read 3.5%.

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Drug Manufacturers - General listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
LLYLilly(Eli) & Co $1.2T —
JNJJohnson & Johnson $658.0B —
ABBVAbbvie Inc $467.4B —
MRKMerck & Co Inc $371.7B —
NVSNovartis AG - ADR $306.5B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold BIIB

22 of the 216 funds whose filed holdings we currently hold own BIIB shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns BIIB.

Shariah funds
FundBIIB in fundFund compliant by weight
MNZL Manzil Russell Halal USA Broad Market ETF 0.10% 88%
HLAL Wahed FTSE USA Shariah ETF 0.09% 72%
SPUS SP Funds S&P 500 Sharia Industry Exclusions ETF 0.08% 79%
You may already own it

Widely held U.S. index funds. If you own one, you own BIIB through it. None of them is a Shariah fund; the last column is our look-through of each.

FundBIIB in fundFund compliant by weight
RSP Invesco S&P 500 Equal Weight ETF 0.20% 44%
SPY 0.05% 56%
VOO VANGUARD 500 INDEX FUND 0.05% 56%
SPYM State Street(R) SPDR(R) Portfolio S&P 500(R) ETF 0.05% 56%
IVV iShares Core S&P 500 ETF 0.05% 56%
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.04% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.04% 54%
SCHB Schwab U.S. Broad Market ETF 0.04% 53%
Other funds
FundBIIB in fundFund compliant by weight
ALOAX ALGER MID CAP FOCUS FUND 2.10% 57%
ALCCX ALGER CAPITAL APPRECIATION FUND 0.54% 54%
FLCV Federated Hermes MDT Large Cap Value ETF 0.29% 42%
SELCX SIMT Large Cap Growth Fund 0.22% 62%
CIHEX Calamos Hedged Equity Fund 0.07% 53%
XTR Global X S&P 500 Tail Risk ETF 0.05% 53%
GRMIX Nationwide S&P 500 Index Fund 0.05% 53%
MLRG iShares Morningstar U.S. Equity ETF 0.05% 55%
TLSTX Nuveen Life Stock Index Fund 0.04% 53%
AMONX AQR Large Cap Momentum Style Fund 0.04% 55%
1 more fund
FundBIIB in fundFund compliant by weight
POMIX T. Rowe Price Total Equity Market Index Fund 0.03% 53%

Sorted by BIIB’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names BIIB once, so a bond is not counted as the shares; 4 more funds name BIIB in a way we cannot separate from its bonds, and are not listed. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding BIIB
InvestorFirmPositionWeightAs of
Ken Griffin Citadel Advisors $442M 0.0% 2026-09-30
Hotchkis & Wiley Hotchkis & Wiley Capital Management $152M 0.4% 2026-09-30
Ken Fisher Fisher Asset Management $82M 0.0% 2026-09-30
Israel Englander Millennium Management $75M 0.0% 2026-09-30
Joel Greenblatt Gotham Asset Management $57M 0.1% 2026-09-30
Samantha McLemore Patient Capital Management $56M 1.8% 2026-09-30
David Shaw D. E. Shaw & Co. $17M 0.0% 2026-09-30
Larry Robbins Glenview Capital Management $15M 0.3% 2026-09-30
Paul Tudor Jones Tudor Investment Corp $6M 0.0% 2026-09-30
Mark Hillman Hillman Capital Management $5M 3.9% 2026-09-30
John Hussman Hussman Strategic Advisors $5M 1.0% 2026-09-30
Jefferies Jefferies Financial Group $4M 0.0% 2026-09-30
Jeff Auxier Auxier Asset Management $2M 0.3% 2026-06-30
Ron Baron Baron Capital (BAMCO) $2M 0.0% 2026-09-30
Sallie Krawcheck Ellevest $1M 0.1% 2026-09-30
Steven Cohen Point72 Asset Management $1M 0.0% 2026-09-30
Wahed Invest Wahed Invest LLC $1M 0.1% 2026-06-30
Azzad Asset Management Azzad Asset Management $1M 0.1% 2026-09-30
Lee Ainslie Maverick Capital $1M 0.0% 2026-09-30
Peter Brown Renaissance Technologies $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

254.87232.26209.64187.03164.422025-11-182026-05-202026-11-17

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
244.96
S2
247.80
S1
249.73
PIVOT
252.57
R1
254.50
R2
257.34
R3
259.27

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
208.22 – 237.56
±6.58% from 222.89, made 2026-10-06 · resolves 2026-10-13
STRONG BUY
from 19 indicators
74.1% of our last 15548 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 50.3% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG BUY
19 indicators
OscillatorsSTRONG BUY
2 buy · 4 neutral · 1 sell
Moving averagesSTRONG BUY
10 buy · 0 neutral · 2 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)56.00NEUTRAL
Stochastic %K (14)51.38NEUTRAL
CCI (20)0.26NEUTRAL
Williams %R (14)-48.62NEUTRAL
MACD (12,26,9)-0.90SELL
ROC (10)0.75BUY
Momentum (10)1.86BUY
EMA (10)251.10SELL
SMA (10)251.46SELL
EMA (20)248.00BUY
SMA (20)250.52BUY
EMA (30)244.25BUY
SMA (30)243.74BUY
EMA (50)237.54BUY
SMA (50)234.73BUY
EMA (100)225.46BUY
SMA (100)222.09BUY
EMA (200)209.11BUY
SMA (200)205.87BUY

About BIIB

Healthcare · Drug Manufacturers - General

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

biogen.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-11-03

MOM
Type · SCALP
251.82
Entry
245.99
Stop
263.49
Target
WIN
Outcome · exit 254.46 (+1.05%)

Stop 245.99 Now 250.79 Target 263.49

Verdict

🟡 BULLISH LEAN

The main driver: outperforming the market by 7.2%, RSI in healthy zone, Wall Street broadly bullish. More signals pointing up than down. Not full confluence yet, but the weight of evidence is bullish. Use `!alert BIIB [level]` to catch the entry, or `!plan BIIB` to size small.

Scores: 3 bullish / 2 bearish

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily RANGING 64
⏰ 4H BULLISH 37
🕐 1H RANGING 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+0.7%
Rate of change (10d)
2.9×
Volume vs its 20-day average
4.84
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

BEARISH   0 buys · 2 sells

Recent: Minor Lloyd sold 3282 sh @ $203.34 (2026-08-03); Minor Lloyd sold 2689 sh @ $200.96 (2026-08-04)

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.